Clinical Trials for Patients with Psoriatic Arthritis

By |

PROTOCOL IM011055: A Multi-center, Randomized, Double-blind,
Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of
Deucravacitinib in Participants with Active Psoriatic Arthritis (PsA) who are
Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or had Previously
Received TNFα Inhibitor Treatment

Study Website:
https://www.bmsstudyconnect.com/content/studyconnect/us/en/clinical-
trials/NCT04908189.html?id=NCT04908189&location=Minnesota&geo_lati=46.729553
&geo_long=-94.6858998


Clinicaltrial.gov website:
https://clinicaltrials.gov/ct2/show/NCT04908189?cond=Psoriatic+Arthritis&cntry=US&s
tate=US%3AMN&city=Eagan&draw=2&rank=4

PROTOCOL TILD-19-07 A Phase III, Randomized, Double-Blind, Placebo-
Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in
Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)

Study Website:


Clinicaltrial.gov website:
https://clinicaltrials.gov/ct2/show/NCT04991116

PROTOCOL VTX958 A Phase 2, Multicenter, Randomized, Double-Blind,
Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of
VTX958 in Patients with Active Psoriatic Arthritis
VTX958 versus Placebo for the Treatment of Active Psoriatic Arthritis VTX958-203


Study Website:
https://ventyxbio.com/pipeline/


Clinicatrial.gov website:
https://www.clinicaltrials.gov/ct2/show/NCT05715125

PROTOCOL SOLSTICE PSA-3005 A Phase 3B, Multicenter, Randomized,
Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of
Guselkumab Administered Subcutaneously in Participants With Active Psoriatic
Arthritis Who Had an Inadequate Response and/or Intolerance to One Prior Anti-
Tumor Necrosis Factor Alpha Agent

Clinicatrial.gov Website:
https://www.clinicaltrials.gov/ct2/show/NCT04936308?recrs=a&cond=Psoriatic+Art
hritis&cntry=US&state=US%3AMN&city=Eagan&draw=2&rank=5

PROTOCOL STAR PSA4002 A Phase 4, Multicenter, Randomized, Double-
blind, Placebo-controlled Study Evaluating the Efficacy and Safety of
Guselkumab Administered Subcutaneously in Bio-naive Participants With Active
Psoriatic Arthritis Axial Disease

Clinicaltrial.gov website:
https://www.clinicaltrials.gov/ct2/show/NCT04929210?recrs=a&cond=Psoriatic+Arthriti
s&cntry=US&state=US%3AMN&city=Eagan&draw=2&rank=6

St Paul Rheumatology